128 related articles for article (PubMed ID: 34115936)
1. Ratiometric Fluorescence Monitoring of Antibody-Guided Drug Delivery to Cancer Cells.
Poplinger D; Bokan M; Hesin A; Thankarajan E; Tuchinsky H; Gellerman G; Patsenker L
Bioconjug Chem; 2021 Aug; 32(8):1641-1651. PubMed ID: 34115936
[TBL] [Abstract][Full Text] [Related]
2. Quantification of Drug Release Degree
Thankarajan E; Jadhav S; Luboshits G; Gellerman G; Patsenker L
Anal Chem; 2021 Jun; 93(23):8265-8272. PubMed ID: 34080851
[TBL] [Abstract][Full Text] [Related]
3. Theranostic system for ratiometric fluorescence monitoring of peptide-guided targeted drug delivery.
Rozovsky A; Ebaston TM; Zaporozhets A; Bazylevich A; Tuchinsky H; Patsenker L; Gellerman G
RSC Adv; 2019 Oct; 9(56):32656-32664. PubMed ID: 35529716
[TBL] [Abstract][Full Text] [Related]
4. Peptide-Driven Targeted Drug-Delivery System Comprising Turn-On Near-Infrared Fluorescent Xanthene-Cyanine Reporter for Real-Time Monitoring of Drug Release.
Ebaston TM; Rozovsky A; Zaporozhets A; Bazylevich A; Tuchinsky H; Marks V; Gellerman G; Patsenker LD
ChemMedChem; 2019 Oct; 14(19):1727-1734. PubMed ID: 31403246
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.
Kobus T; Zervantonakis IK; Zhang Y; McDannold NJ
J Control Release; 2016 Sep; 238():281-288. PubMed ID: 27496633
[TBL] [Abstract][Full Text] [Related]
6. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases.
Zafir-Lavie I; Sherbo S; Goltsman H; Badinter F; Yeini E; Ofek P; Miari R; Tal O; Liran A; Shatil T; Krispel S; Shapir N; Neil GA; Benhar I; Panet A; Satchi-Fainaro R
J Control Release; 2018 Dec; 291():80-89. PubMed ID: 30342077
[TBL] [Abstract][Full Text] [Related]
7. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
8. Activatable bispecific liposomes bearing fibroblast activation protein directed single chain fragment/Trastuzumab deliver encapsulated cargo into the nuclei of tumor cells and the tumor microenvironment simultaneously.
Tansi FL; Rüger R; Böhm C; Steiniger F; Kontermann RE; Teichgraeber UK; Fahr A; Hilger I
Acta Biomater; 2017 May; 54():281-293. PubMed ID: 28347861
[TBL] [Abstract][Full Text] [Related]
9. Homogeneous plate based antibody internalization assay using pH sensor fluorescent dye.
Nath N; Godat B; Zimprich C; Dwight SJ; Corona C; McDougall M; Urh M
J Immunol Methods; 2016 Apr; 431():11-21. PubMed ID: 26851520
[TBL] [Abstract][Full Text] [Related]
10. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.
Frank RT; Edmiston M; Kendall SE; Najbauer J; Cheung CW; Kassa T; Metz MZ; Kim SU; Glackin CA; Wu AM; Yazaki PJ; Aboody KS
PLoS One; 2009 Dec; 4(12):e8314. PubMed ID: 20016813
[TBL] [Abstract][Full Text] [Related]
11. A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action.
Zhang X; Chen J; Weng Z; Li Q; Zhao L; Yu N; Deng L; Xu W; Yang Y; Zhu Z; Huang H
Mol Immunol; 2020 Mar; 119():48-58. PubMed ID: 31978707
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab-conjugated liposome-coated fluorescent magnetic nanoparticles to target breast cancer.
Jang M; Yoon YI; Kwon YS; Yoon TJ; Lee HJ; Hwang SI; Yun BL; Kim SM
Korean J Radiol; 2014; 15(4):411-22. PubMed ID: 25053899
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
Wyatt EA; Davis ME
Mol Pharm; 2020 Feb; 17(2):717-721. PubMed ID: 31916770
[TBL] [Abstract][Full Text] [Related]
14. Herceptin-decorated paclitaxel-loaded poly(lactide-
Zhong S; Ling Z; Zhou Z; He J; Ran H; Wang Z; Zhang Q; Song W; Zhang Y; Luo J
Pharm Dev Technol; 2020 Apr; 25(4):454-463. PubMed ID: 31873051
[TBL] [Abstract][Full Text] [Related]
15. Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery.
Huang R; Sun Y; Zhang XY; Sun BW; Wang QC; Zhu J
Biomed Pharmacother; 2015 Jul; 73():116-22. PubMed ID: 26211591
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer.
You Y; Xu Z; Chen Y
Drug Deliv; 2018 Nov; 25(1):448-460. PubMed ID: 29405790
[TBL] [Abstract][Full Text] [Related]
18. Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer.
Knutson S; Raja E; Bomgarden R; Nlend M; Chen A; Kalyanasundaram R; Desai S
PLoS One; 2016; 11(6):e0157762. PubMed ID: 27336622
[TBL] [Abstract][Full Text] [Related]
19. High-sensitivity detection of breast tumors in vivo by use of a pH-sensitive near-infrared fluorescence probe.
Mathejczyk JE; Pauli J; Dullin C; Resch-Genger U; Alves F; Napp J
J Biomed Opt; 2012 Jul; 17(7):076028. PubMed ID: 22894511
[TBL] [Abstract][Full Text] [Related]
20. Generation and Biological Evaluation of Fc Antigen Binding Fragment-Drug Conjugates as a Novel Antibody-Based Format for Targeted Drug Delivery.
Jäger S; Wagner TR; Rasche N; Kolmar H; Hecht S; Schröter C
Bioconjug Chem; 2021 Aug; 32(8):1699-1710. PubMed ID: 34185508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
